Study guide

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders

Key Takeaways Explain This Topic AI

Primary hemostasis encompasses localized vasoconstriction, platelet adhesion to subendothelial collagen via von Willebrand Factor (vWF) binding Glycoprotein Ib/IX/V (GPIb), shape change and granule secretion, and platelet aggregation mediated by Glycoprotein IIb/IIIa (GPIIb/IIIa) binding fibrinogen.

Light transmission aggregometry (LTA) measures clearing of platelet-rich plasma (PRP); biphasic curves occur with physiological concentrations of ADP and epinephrine, collagen exhibits a characteristic lag phase, arachidonic acid produces a rapid single wave, and ristocetin induces vWF-GPIb agglutination independent of metabolic activation.

Bernard-Soulier Syndrome (BSS) is an inherited deficiency of the GPIb/IX/V complex (CD42b/CD42a) characterized by giant platelets, moderate thrombocytopenia, and absent ristocetin agglutination that DOES NOT correct upon the addition of normal plasma or exogenous vWF.

Glanzmann Thrombasthenia (GT) is an inherited deficiency or dysfunction of the GPIIb/IIIa integrin complex (CD41/CD61) presenting with normal platelet count and morphology, severe mucocutaneous bleeding, absent aggregation with ADP, collagen, epinephrine, and arachidonic acid, but completely normal agglutination with ristocetin.

Storage pool diseases include dense granule deficiencies (Hermansky-Pudlak, Chédiak-Higashi, Wiskott-Aldrich) with loss of the secondary aggregation wave, and alpha granule deficiency (Gray Platelet Syndrome, NBEAL2 mutation) presenting with large, agranular, ghost-like gray platelets on Wright stain.

Last updated: August 2026

Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders

Primary hemostasis is the rapid, highly coordinated physiological response triggered by vascular endothelial injury. Its ultimate objective is the formation of an initial, friable primary platelet plug (hemostatic plug) within seconds of vessel wall disruption. This process depends on precise interactions between the injured vessel wall, subendothelial extracellular matrix macromolecules, multimeric plasma proteins, and specialized platelet surface glycoprotein receptors. [ INJURY TO VESSEL WALL ]

  • │
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • [ LOCAL VASOCONSTRICTION ] [ SUBENDOTHELIAL EXPOSURE ]
  • Endothelin-1 release - Type I & III Collagen fibers
  • Neurogenic reflex spasm - Matrix-bound vWF
  • │ │
  • └───────────────────────┬───────────────────────┘
  • ▼
  • [ 1. PLATELET ADHESION ]
  • vWF A1 domain binds Platelet GPIb/IX/V (Shear-dependent tethering)
  • Direct collagen binding: GP Ia/IIa (α2β1 integrin) & GP VI (Signaling)
  • │
  • ▼
  • [ 2. ACTIVATION & SHAPE CHANGE ]
  • PLC & PLA2 activation ──► Arachidonic Acid ──► COX-1 ──► TxA2 synthesis
  • Disc-to-sphere transition with filopodia / pseudopod extension
  • Granule exocytosis (Dense & Alpha granules via Open Canalicular System)
  • │
  • ▼
  • [ 3. PLATELET AGGREGATION ]
  • Inside-out signaling activates GPIIb/IIIa (αIIbβ3 integrin)
  • Conformational opening binds Divalent Fibrinogen (and vWF)
  • Inter-platelet bridging network forms [ PRIMARY HEMOSTATIC PLUG ]
  • The Four Sequential Stages of Primary Hemostasis
  • 1. Localized Vasoconstriction

Immediately upon physical trauma or breach of the endothelial barrier, damaged endothelial cells and local smooth muscle myocytes initiate immediate, localized vasoconstriction:

Neurogenic Reflex: Immediate sympathetic vasomotor reflex response causing transient smooth muscle contraction.

Biochemical Mediators: Endothelial cells release endothelin-1 , a potent 21-amino acid peptide vasoconstrictor. Activated platelets simultaneously secrete serotonin (5-hydroxytryptamine / 5-HT) from dense granules and generate Thromboxane A 2 A_2 A 2 ​ ( T x A 2 TxA_2 T x A 2 ​ ) , maintaining sustained vascular narrowing to reduce localized blood flow and shear forces at the injury site.

2. Platelet Adhesion: Receptors and Shear Dynamics

Under normal laminar blood flow, platelets circulate in an inactive, discoid state without adhering to intact, prostacyclin- ( P G I 2 PGI_2 PG I 2 ​ ) and nitric oxide- (NO) coated endothelium. When vascular integrity is breached, circulating platelets adhere to exposed subendothelial structures: PLASMA / LUMEN

  • ─────────────────────────────────────────────────────────────────────────────
  • [ Platelet Membrane ]
  • │ │ │ │
  • [GPIb/IX/V] [GPIIb/IIIa] [GP Ia/IIa] [GP VI]
  • (CD42b/a) (CD41/CD61) (α2β1 Integrin) (Ig Superfamily)
  • │ │ │ │
  • ═══════╪══════════════╪═════════════════╪══════════════════════╪═════════════
  • SUBENDOTHELIUM
  • │ │ │ │
  • [ vWF ] [ Fibrinogen ] [ Collagen ] [ Collagen ]
  • │ (Aggregation) (Direct Anchor) (PLCγ Activation)
  • [ Collagen ]
  • ─────────────────────────────────────────────────────────────────────────────

High Shear Stress Adhesion (Microvasculature and Arteries): Under high shear rates ( > 1 , 000 s − 1 >1,000\text{ s}^{-1} > 1 , 000 s − 1 ), direct collagen-platelet binding is kinetically unfavorable. Subendothelial Type I and Type III collagen binds the A3 domain of multimeric von Willebrand Factor (vWF) . Shear forces uncoil vWF, exposing its A1 domain , which binds with high affinity to the platelet surface Glycoprotein Ib/IX/V (GPIb/IX/V) complex (specifically the N-terminal globular domain of the GPIb α \alpha α subunit, marked by CD42b ). This transient tethering slows down circulating platelets ("platelet rolling").

Direct Collagen Binding (Low Shear / Stable Arrest): Once rolling is established, direct receptors lock the platelet to collagen:

Glycoprotein Ia/IIa (GP Ia/IIa / Integrin α 2 β 1 \alpha_2\beta_1 α 2 ​ β 1 ​ ): Provides stable, non-covalent adhesion to collagen fibers.

Glycoprotein VI (GP VI): A 62-kDa member of the immunoglobulin superfamily coupled to the Fc receptor γ \gamma γ -chain ( F c R γ FcR\gamma F c R γ ). Collagen binding to GP VI clusters the receptor, initiating tyrosine kinase cascades via Lyn/Fyn and Syk that activate Phospholipase C γ 2 C\gamma_2 C γ 2 ​ ( P L C γ 2 PLC\gamma_2 P L C γ 2 ​ ) to drive robust intracellular activation.

3. Platelet Activation, Intracellular Signaling & Granule Secretion

Engagement of GP VI, GPIb/IX/V, and soluble agonists (thrombin, ADP, T x A 2 TxA_2 T x A 2 ​ ) triggers a rapid surge in cytosolic free ionized calcium ( C a 2 + Ca^{2+} C a 2 + ) from the dense tubular system (DTS):

Phospholipase C (PLC) Pathway: Cleaves membrane phosphatidylinositol 4,5-bisphosphate ( P I P 2 PIP_2 P I P 2 ​ ) into inositol 1,4,5-trisphosphate ( I P 3 IP_3 I P 3 ​ ) and diacylglycerol (DAG) . I P 3 IP_3 I P 3 ​ mobilizes calcium from the DTS, while DAG activates protein kinase C (PKC).

Phospholipase A 2 A_2 A 2 ​ ( P L A 2 PLA_2 P L A 2 ​ ) & Arachidonic Acid Cascade: Elevated cytosolic C a 2 + Ca^{2+} C a 2 + activates cytosolic P L A 2 PLA_2 P L A 2 ​ , which hydrolyzes membrane phospholipids to liberate free arachidonic acid . Cyclooxygenase-1 (COX-1 / Prostaglandin G/H Synthase 1) converts arachidonic acid to prostaglandin G 2 G_2 G 2 ​ ( P G G 2 PGG_2 PG G 2 ​ ) and prostaglandin H 2 H_2 H 2 ​ ( P G H 2 PGH_2 PG H 2 ​ ). Thromboxane synthase then converts P G H 2 PGH_2 PG H 2 ​ into Thromboxane A 2 A_2 A 2 ​ ( T x A 2 TxA_2 T x A 2 ​ ) . T x A 2 TxA_2 T x A 2 ​ diffuses across the platelet membrane to bind G q G_q G q ​ -coupled thromboxane receptors ( T P α / T P β TP\alpha/TP\beta TP α / TPβ ), amplifying calcium flux and recruiting adjacent platelets.

Morphologic Shape Change: Rearrangement of the marginal microtubule band and actin polymerization transforms the smooth biconcave disc into a spherical cell with long, branching pseudopods (filopodia), dramatically increasing surface area and facilitating platelet-platelet contact.

Granule Secretion: Platelet storage granules fuse with the Open Canalicular System (OCS) and plasma membrane, discharging their contents into the localized microenvironment:

Granule Type Key Molecular Constituents Functional Role in Hemostasis

Dense Granules ( δ \delta δ -Granules) ; (3–8 per platelet; visible on whole-mount electron microscopy) ADP (Adenosine diphosphate), ATP , Serotonin (5-HT), Ionized Calcium ( C a 2 + Ca^{2+} C a 2 + ) , Pyrophosphate, Magnesium ADP binds P 2 Y 1 P2Y_1 P 2 Y 1 ​ ( G q G_q G q ​ -coupled: shape change, initial aggregation) and P 2 Y 12 P2Y_{12} P 2 Y 12 ​ ( G i G_i G i ​ -coupled: adenylate cyclase inhibition, sustained GPIIb/IIIa activation); serotonin promotes vasoconstriction; C a 2 + Ca^{2+} C a 2 + is essential for tenase/prothrombinase assembly.

Alpha Granules ( α \alpha α -Granules) ; (50–80 per platelet; membrane-bound) Fibrinogen , vWF , Factor V , Factor XI , Protein S , Platelet Factor 4 (PF4) , β \beta β -Thromboglobulin ( β \beta β -TG) , Platelet-Derived Growth Factor (PDGF) , Transforming Growth Factor- β \beta β (TGF- β \beta β ) , P-Selectin (CD62P) Discharges high local concentrations of coagulation factors; PF4 neutralizes endothelial heparan sulfate and heparin; PDGF/TGF- β \beta β promote smooth muscle migration and tissue repair; CD62P translocates to external membrane to bind leukocyte PSGL-1.

Lysosomes ( λ \lambda λ -Granules) Acid hydrolases, elastase, collagenase, cathepsins Cleaves extracellular matrix components during late clot remodeling and vessel repair.

4. Platelet Aggregation: The GPIIb/IIIa Fibrinogen Bridge

Platelet aggregation is the cohesion of activated platelets to one another to form the definitive primary plug:

Conformational Activation of Integrin α I I b β 3 \alpha_{IIb}\beta_3 α II b ​ β 3 ​ (GPIIb/IIIa): In resting platelets, GPIIb/IIIa (a heterodimer composed of CD41 and CD61, with ~80,000 copies per platelet) exists in a low-affinity, bent conformation. Inside-out signaling mediated by talin-1 and kindlin-3 binding to the cytoplasmic β 3 \beta_3 β 3 ​ tail drives a rapid hinge extension into a high-affinity, open conformation.

Divalent Fibrinogen Crosslinking: The activated GPIIb/IIIa complex exposes binding sites for the RGD (Arg-Gly-Asp) peptide motifs on the symmetrical, dimeric plasma protein fibrinogen (and vWF under high shear). In the presence of extracellular C a 2 + Ca^{2+} C a 2 + , each fibrinogen molecule binds two distinct GPIIb/IIIa receptors on adjacent platelets, constructing a resilient, crosslinked platelet lattice.

Platelet Aggregometry: Light Transmission Aggregometry (LTA)

Developed by Gustav Born, Light Transmission Aggregometry (LTA) remains the historical reference method and gold standard for evaluating qualitative platelet disorders. [ LTA PRINCIPLE ]

  • LIGHT SOURCE ──► [ Turbid PRP ] (Resting) ──► DETECTOR ──► Low Light Transmittance (0%)
  • │
  • + AGONIST (Stirred at 37°C)
  • ▼
  • LIGHT SOURCE ──► [ Platelet Clumps + Clear Plasma ] ──► DETECTOR ──► High Light Transmittance (100%)
  • Principle of LTA

Citrated blood is gently centrifuged to yield Platelet-Rich Plasma (PRP) (turbid, high optical density) and Platelet-Poor Plasma (PPP) (clear baseline blank, representing 100% light transmittance).

PRP is maintained at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C in a cuvette with continuous magnetic stirring (1,000 rpm). A specific platelet agonist is introduced, and changes in light transmittance are recorded over time:

Baseline: Turbid suspension transmits minimal light ( 0 % 0\% 0% transmittance).

Shape Change: Initial disc-to-sphere transition produces a slight decrease in transmittance (small downward deflection).

Primary Wave: Agonist binds surface receptors, inducing direct GPIIb/IIIa activation and primary, reversible platelet-platelet cohesion.

Secondary Wave: In response to sufficient stimulation, platelets secrete endogenous dense-granule ADP and synthesize T x A 2 TxA_2 T x A 2 ​ , driving irreversible secondary aggregation (accompanied by full plasma clearing and maximal light transmittance).

Agonist-Specific Response Profiles

Adenosine Diphosphate (ADP): At low-to-moderate concentrations ( 1.0 to 2.5 μ mol/L 1.0\text{ to }2.5\text{ }\mu\text{mol/L} 1.0 to 2.5 μ mol/L ), produces a classic biphasic curve (primary wave via P 2 Y 1 P2Y_1 P 2 Y 1 ​ , followed by secondary secretion wave via P 2 Y 12 P2Y_{12} P 2 Y 12 ​ ). At high concentrations ( > 5.0 μ mol/L >5.0\text{ }\mu\text{mol/L} > 5.0 μ mol/L ), the two waves merge into a single broad, irreversible curve.

Epinephrine (Adrenaline): Binds platelet α 2 A \alpha_{2A} α 2 A ​ -adrenergic receptors ( G z G_z G z ​ -coupled). Produces a distinct biphasic curve with no shape change deflection. Epinephrine requires an intact cyclooxygenase pathway and granule release to achieve full aggregation.

Collagen: Exhibits a distinct lag phase (1 to 2 minutes) while collagen fibrils polymerize and engage GP VI receptors. Once signaling threshold is reached, it produces a single, steep, irreversible wave that is entirely dependent on endogenous T x A 2 TxA_2 T x A 2 ​ synthesis and dense granule secretion.

Arachidonic Acid (AA): Directly provides the substrate for COX-1, bypassing surface receptor cascades. Generates a rapid, steep, single-wave aggregation curve without a lag phase.

Ristocetin: An antibiotic that induces agglutination (passive physical binding) rather than metabolic aggregation. Ristocetin binds plasma vWF, altering its conformation so that its A1 domain binds platelet GPIb/IX/V, even in resting, metabolically inactive, or formalin-fixed platelets.

Qualitative Platelet Disorders: Diagnostic Matrix

Disorder Primary Molecular / Structural Defect Platelet Count & Smear Morphology Aggregometry with ADP, Epinephrine & Collagen Aggregometry with Arachidonic Acid Response to Ristocetin Diagnostic Flow Cytometry / Confirmatory Tests

Bernard-Soulier Syndrome (BSS) Inherited autosomal recessive deficiency/mutation of GPIb/IX/V complex ( GP1BA, GP1BB, GP9 genes). Mild-to-moderate thrombocytopenia ( 20 – 100 × 10 9 / L 20\text{--}100\times 10^9/\text{L} 20 – 100 × 1 0 9 / L ); Giant platelets ( 4 – 8 μ m 4\text{--}8\text{ }\mu\text{m} 4 – 8 μ m , size of lymphocytes); increased MPV. NORMAL aggregation with ADP, Epi, and Collagen. NORMAL aggregation. ABSENT / MARKEDLY DECREASED agglutination.; (Crucial: DOES NOT correct with normal plasma/vWF). CD42b (GPIb α \alpha α ) and CD42a (GPIX) NEGATIVE / severely reduced; CD41/CD61 normal.

Glanzmann Thrombasthenia (GT) Inherited autosomal recessive deficiency/mutation of GPIIb/IIIa complex ( ITGA2B, ITGB3 genes). Strictly NORMAL platelet count ( 150 – 450 × 10 9 / L 150\text{--}450\times 10^9/\text{L} 150 – 450 × 1 0 9 / L ); NORMAL platelet morphology. ABSENT aggregation across all standard concentrations of ADP, Epi, and Collagen. ABSENT aggregation. Strictly NORMAL agglutination.; (Primary wave intact; no secondary aggregation). CD41 (GPIIb) and CD61 (GPIIIa) NEGATIVE / severely reduced; CD42a/CD42b normal.

Dense Granule Deficiency ( δ \delta δ -Storage Pool Disease) Quantitative reduction in dense granule number/content (Hermansky-Pudlak, Chédiak-Higashi, Wiskott-Aldrich). Normal to variable count; morphology variable (giant lysosomal granules in Chédiak-Higashi). Loss of secondary wave with ADP and Epinephrine; Absent / markedly blunted aggregation with Collagen. Normal to impaired. NORMAL agglutination. Electron microscopy demonstrates absence of dense granules; decreased ATP:ADP ratio ( < 1.5 : 1 <1.5:1 < 1.5 : 1 , normal > 2.5 : 1 >2.5:1 > 2.5 : 1 ).

Gray Platelet Syndrome ( α \alpha α -Storage Pool Disease) Autosomal recessive mutation in N B E A L 2 NBEAL2 NBE A L 2 gene causing failure of alpha granule packaging. Moderate thrombocytopenia ( 30 – 100 × 10 9 / L 30\text{--}100\times 10^9/\text{L} 30 – 100 × 1 0 9 / L ); Large, agranular, pale slate-gray platelets on Wright stain. Variable mild-to-moderate impairment of aggregation with Collagen and Thrombin; ADP/Epi variable. Usually normal. NORMAL agglutination. Wright-Giemsa smear shows characteristic "ghost-like" gray platelets; depleted PF4, β \beta β -TG, and PDGF in platelet lysate; progressive marrow myelofibrosis.

Aspirin Ingestion (Acquired COX-1 Inhibition) Irreversible acetylation of Ser529 in COX-1 , blocking T x A 2 TxA_2 T x A 2 ​ synthesis for the entire platelet lifespan (7–10 days). Strictly NORMAL count and morphology. Loss of secondary wave with low-dose ADP and Epinephrine; blunted response to low-dose Collagen. COMPLETELY ABSENT aggregation with Arachidonic Acid. Strictly NORMAL agglutination. PFA-100/200: Prolonged Collagen/Epinephrine closure time; Normal Collagen/ADP closure time.

von Willebrand Disease (vWD) (Extrinsic to Platelet) Quantitative (Type 1, Type 3) or qualitative (Type 2) deficiency in plasma von Willebrand Factor . Normal count (except Type 2B: mild thrombocytopenia); normal morphology. NORMAL aggregation with ADP, Epi, Collagen, and Arachidonic Acid. NORMAL aggregation. ABSENT / REDUCED agglutination.; (Crucial: CORRECTS to normal upon addition of normal plasma/cryoprecipitate). vWF Antigen (vWF:Ag) decreased; Ristocetin Cofactor (vWF:RCo) decreased; normal platelet flow cytometry (CD42b+).